Therefore, it is biologically plausible that the putative risk genotypes in PTEN/AKT/mTOR axis are implicated in the progression of PCa, indicating that this pathway is an exciting and rational molecular target for therapy in PCa. The gene discussed is AKT1; the disease is posterior cortical atrophy.